Corporate ActionMay 15, 2026, 08:28 AM
Silexion Therapeutics Raises $1M from Warrant Exercise
AI Summary
Silexion Therapeutics Corp. announced it has entered into definitive agreements for the immediate exercise of certain outstanding warrants, expecting to generate approximately $1 million in gross proceeds. The exercise involves 1,995,092 ordinary shares at a reduced price of $0.50 per share. In consideration, the company will issue new unregistered Series C and Series D warrants, totaling nearly 4 million shares, also with an exercise price of $0.50 per share, exercisable upon shareholder approval. The net proceeds will be used for general corporate purposes and working capital.
Key Highlights
- Silexion Therapeutics to receive approximately $1 million in gross proceeds from warrant exercise.
- 1,995,092 outstanding warrants exercised at a reduced price of $0.50 per share.
- Company to issue new unregistered Series C warrants for up to 2,045,000 ordinary shares.
- Company to issue new unregistered Series D warrants for up to 1,945,184 ordinary shares.
- New warrants have an exercise price of $0.50 per share, exercisable upon shareholder approval.
- Net proceeds will be used as working capital for general corporate purposes.
- H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Price Impact
More from SLXN